|CytRx Corporation (NASDAQ:CYTR) Soars 19% On ongoing phase 1b aldoxorubicin combination studies|
|By Marilyn Mullen|
|Tuesday, 05 May 2015 01:16|
specializing in oncology, has confirmed an interim analysis from the two ongoing phase 1b aldoxorubicin combination studies combining aldoxorubicin with either gemcitabine or ifosfamide.
Both studies add standard doses of gemcitabine with more aldoxorubicin. The combinations seem to be reasonably tolerated. Good response has been observed in tumor cases. Aldoxorubicin may become a potent weapon against chemotherapy resistant cancers.
Dr. Sant Chawla, Principal Investigator and Director of the Sarcoma Oncology Center, Santa Monica, CA, expressed excitement on the tolerability of the combinations and added that the first patient demonstrated complete tumor response after just five cycles of combination for about half a year.
He added that the studies show that possibility of combinations in outcomes of clinical trials.
The study number one is Phase 1b clinical trial which is investigating on the preliminary safety of aldoxorubicin plus ifosfamide for first-line treatment of patients with advanced bone cancer.
The second trial is a clinical trial investigating preliminary safety of ascending doses of aldoxorubicin plus gemcitabine in patients with advanced, unresectable, metastatic solid tumors that have either relapsed or were refractory to treatment following at least one prior chemotherapy for which no standard approved therapy exists. Tumor shrinkage was observed in most patients.
Steven A. Kriegsman, Chairman and CEO of CytRx, opined that aldoxorubicin has potential to be combined with other anti-cancer agents for improving patient outcomes for various cancer types. He added that results include excellent tolerability as well as compelling initial signs of activity giving an opportunity to expand aldoxorubicin development pipeline and exploring additional indications.
He further added that the initial results look encouraging and that the firm is keen on giving updates on the studies as they reach completion.
Shares of the company were up over 19% to $4.41.